Optimal diagnosis and management of non-alcoholic fatty liver disease.
出版信息
Asian Biomed (Res Rev News). 2022 Feb 28;16(1):1-2. doi: 10.2478/abm-2022-0001. eCollection 2022 Feb.
Abstract
摘要
相似文献
1
Optimal diagnosis and management of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的优化诊断与管理
Asian Biomed (Res Rev News). 2022 Feb 28;16(1):1-2. doi: 10.2478/abm-2022-0001. eCollection 2022 Feb.
2
[Non-alcoholic fatty liver disease and steatohepatitis].[非酒精性脂肪性肝病和脂肪性肝炎]
Orv Hetil. 2013 Jul 21;154(29):1124-34. doi: 10.1556/OH.2013.29626.
3
Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management.非酒精性脂肪性肝病：流行病学、风险因素、诊断和治疗的综述。
Intern Med J. 2020 Sep;50(9):1038-1047. doi: 10.1111/imj.14709.
4
Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey.基层医疗与转诊医生对非酒精性脂肪性肝病管理的看法：一项全国性调查。
Therap Adv Gastroenterol. 2021 Sep 20;14:17562848211042200. doi: 10.1177/17562848211042200. eCollection 2021.
5
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.脂肪肝指数（FLI）在非酒精性脂肪性肝病管理中的作用：一项系统评价
Diagnostics (Basel). 2023 Oct 26;13(21):3316. doi: 10.3390/diagnostics13213316.
6
[Diagnosis and therapeutic strategies for non-obese type of non-alcoholic fatty liver diseases].非肥胖型非酒精性脂肪性肝病的诊断与治疗策略
Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):203-207. doi: 10.3760/cma.j.cn501113-20191226-00480.
7
Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease.乳糜泻诊断后非酒精性脂肪性肝病风险增加。
J Hepatol. 2015 Jun;62(6):1405-11. doi: 10.1016/j.jhep.2015.01.013. Epub 2015 Jan 21.
8
Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中心血管疾病的病理生理机制
Gastroenterol Hepatol Bed Bench. 2022 Summer;15(3):194-203. doi: 10.22037/ghfbb.v15i3.2549.
9
Review article: Non-alcoholic fatty liver disease.综述文章：非酒精性脂肪性肝病
Aliment Pharmacol Ther. 2003 Apr;17(8):977-86. doi: 10.1046/j.1365-2036.2003.01493.x.
10
Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study.非酒精性脂肪性肝病患者的自我管理及相关因素：一项横断面研究。
Int J Environ Res Public Health. 2022 Dec 30;20(1):667. doi: 10.3390/ijerph20010667.
本文引用的文献
1
Association between serum uric acid level and non-alcoholic fatty liver disease in Koreans.韩国人血清尿酸水平与非酒精性脂肪性肝病之间的关联。
Asian Biomed (Res Rev News). 2022 Feb 28;16(1):15-22. doi: 10.2478/abm-2022-0003. eCollection 2022 Feb.
2
Abnormal liver enzymes: A review for clinicians.肝功能异常酶：临床医生综述
World J Hepatol. 2021 Nov 27;13(11):1688-1698. doi: 10.4254/wjh.v13.i11.1688.
3
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病相关肝细胞癌的全球流行病学：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238. doi: 10.1038/s41575-020-00381-6. Epub 2020 Dec 21.
4
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. FibroScan-AST (FAST) 评分用于无创识别有显著活动度和纤维化的非酒精性脂肪性肝炎患者：一项前瞻性推导和全球验证研究。
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3.
5
Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management.非酒精性脂肪性肝病：流行病学、风险因素、诊断和治疗的综述。
Intern Med J. 2020 Sep;50(9):1038-1047. doi: 10.1111/imj.14709.
6
Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials.维生素 E 对非酒精性脂肪性肝病的影响：一项随机对照试验的系统评价和荟萃分析。
Postgrad Med J. 2019 Nov;95(1129):601-611. doi: 10.1136/postgradmedj-2018-136364. Epub 2019 Aug 21.
7
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.非酒精性脂肪性肝病临床试验终点的 AASLD/EASL 联合研讨会报告。
Hepatology. 2019 Oct;70(4):1424-1436. doi: 10.1002/hep.30782. Epub 2019 Jul 9.
8
Nonalcoholic fatty liver disease: Definitions, risk factors, and workup.非酒精性脂肪性肝病：定义、危险因素及检查
Clin Liver Dis (Hoboken). 2012 Sep 25;1(4):99-103. doi: 10.1002/cld.81. eCollection 2012 Sep.
9
Current and future pharmacological therapies for NAFLD/NASH.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的当前和未来药理学治疗方法。
J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16.
10
Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.非酒精性脂肪性肝病（NAFLD）——发病机制、分类以及对药物代谢酶和转运体的影响
Drug Metab Rev. 2017 May;49(2):197-211. doi: 10.1080/03602532.2017.1293683. Epub 2017 Mar 17.
Zotero 插件